AKT1 and breast cancer: Furthermore, capivasertib, an AKT inhibitor, has demonstrated efficacy in HR+/HER2− BC patients harboring PIK3CA, AKT1, or PTEN alterations following disease progression on standard adjuvant therapies (19).